NASDAQ: ORMP
Oramed Pharmaceuticals Inc Stock Ownership - Who owns Oramed Pharmaceuticals?

Insider buying vs selling

Have Oramed Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joshua HexterCOO CBO2026-07-0250,000$3.69
$184.50kBuy
Avraham GabayChief Financial Officer2026-07-0173,360$4.51
$330.71kSell
Joshua HexterCOO CBO2026-07-01137,000$4.46
$611.43kSell
Miriam KidronChief Scientific Officer2026-03-30435,084$3.31
$1.44MSell
Nadav KidronPresident and CEO2026-03-3044,818$3.31
$148.35kSell

1 of 1

ORMP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ORMP insiders and whales buy or sell their stock.

ORMP Shareholders

What type of owners hold Oramed Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Zeev Bronfeld16.10%6,589,767$26.56MInsider
Nadav Kidron8.67%3,548,243$14.30MInsider
Bml Capital Management LLC7.74%3,167,231$12.76MInstitution
Regals Capital Management LP6.45%2,640,460$10.64MInsider
Aquamarine Financial Cayman Ltd5.16%2,112,312$8.51MInstitution
Benjamin Shapiro4.94%2,023,220$8.15MInsider
Mercer Global Advisors Inc4.67%1,910,540$7.70MInstitution
Gem Investment Advisors LLC4.01%1,640,069$6.61MInstitution
David Mark Slager3.22%1,316,328$5.30MInsider
Murchinson Ltd3.21%1,315,294$5.30MInstitution

1 of 3

ORMP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ORMP32.35%54.83%Net SellingNet Selling
QSI28.97%48.33%Net BuyingNet Selling
CRBP46.35%53.65%Net SellingNet Buying
ALEC65.03%34.97%Net SellingNet Selling
ADAG5.57%1.43%

Oramed Pharmaceuticals Stock Ownership FAQ

Who owns Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ: ORMP) is owned by 32.35% institutional shareholders, 54.83% Oramed Pharmaceuticals insiders, and 12.82% retail investors. Zeev Bronfeld is the largest individual Oramed Pharmaceuticals shareholder, owning 6.59M shares representing 16.10% of the company. Zeev Bronfeld's Oramed Pharmaceuticals shares are currently valued at $27.41M.

If you're new to stock investing, here's how to buy Oramed Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.